Role of α-Blockers in Type III Prostatitis: A Systematic Review of the Literature
2006; Lippincott Williams & Wilkins; Volume: 177; Issue: 1 Linguagem: Inglês
10.1016/j.juro.2006.08.090
ISSN1527-3792
AutoresVibhash Mishra, John Browne, Mark Emberton,
Tópico(s)Anesthesia and Pain Management
ResumoNo AccessJournal of UrologyReview article1 Jan 2007Role of α-Blockers in Type III Prostatitis: A Systematic Review of the Literatureis accompanied byIdentification of α-1L and α-1A Adrenoceptors in Human Prostate by Tissue Segment Binding Vibhash C. Mishra, John Browne, and Mark Emberton Vibhash C. MishraVibhash C. Mishra Wexham Park Hospital, London, United Kingdom More articles by this author , John BrowneJohn Browne Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom More articles by this author , and Mark EmbertonMark Emberton Institute of Urology and Nephrology, University College London, London, United Kingdom More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.08.090AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined the evidence for the effectiveness of α-blockers for type III prostatitis. Materials and Methods: Studies were identified through a search of MEDLINE®, EMBASE and The Cochrane Library® as well as a manual search of bibliographies of identified articles and abstract books of recent major international urology conferences. Inclusion criteria included randomized, placebo controlled trials of treatment for type III prostatitis and use of the National Institutes of Health-Chronic Prostatitis Symptom Index outcome measure. Results: Six unique trials in a total of 386 patients met inclusion criteria. One study showed no difference between α-blockers and placebo in terms of total or domain National Institutes of Health-Chronic Prostatitis Symptom Index scores and another did not report the p value. All of the remaining 4 studies showed a statistically significant difference in the total score in favor of α-blockers, while only 2 showed improved quality of life. Individual treatment effects were statistically significant more often when treatment was administered for 3 months or longer. Despite a common tool for outcome assessment meta-analysis of the results in individual trials was not possible due to differences in the manner of interpreting outcomes and reporting data. Conclusions: The current published literature is insufficient to conclude with certainty that α-blockers are effective for type III prostatitis. Future studies should incorporate uniformity in data collection and reporting with improved health related quality of life as the end point of therapy. References 1 : Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology1998; 51: 578. Google Scholar 2 : Prevalence and correlates of prostatitis in Health Professionals Follow-up Study Cohort. J Urol2002; 167: 1363. Google Scholar 3 : How common is prostatitis?: A national survey of physician visits. J Urol1998; 159: 1224. Google Scholar 4 : Diagnosis and treatment of prostatitis in Canada. Urology1998; 52: 797. Google Scholar 5 : Chronic prostatitis: what we know, what we do not know, and what we should do!. World J Urol2003; 21: 57. Google Scholar 6 : Sickness impact on chronic nonbacterial prostatitis and its correlates. J Urol1996; 155: 965. Link, Google Scholar 7 : NIH consensus definition and classification of prostatitis. JAMA1999; 282: 236. Google Scholar 8 : The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol1999; 162: 369. Link, Google Scholar 9 : Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002; 59: 870. Google Scholar 10 : α-Blockers: an effective treatment for prostatitis?. Curr Urol Rep2000; 1: 148. Google Scholar 11 : The use of α1-adrenoreceptor antagonists in lower urinary tract symptoms: Beyond benign prostatic hyperplasia. Urology2003; 62: 34. Google Scholar 12 : Editorial: emerging concepts in the management of prostatitis/chronic pelvic pain syndrome. J Urol2003; 169: 597. Link, Google Scholar 13 : Etiology and management of chronic pelvic pain syndrome in men. Urology2004; 63: 75. Google Scholar 14 : Summary Consensus Statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol2003; 2: 1. Google Scholar 15 : Management of chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am2002; 29: 235. Google Scholar 16 : Why alpha-blockers in prostatitis?. Eur Urol2003; 2: 27. Google Scholar 17 : Alpha 1-adrenergic receptor subtypes in human detrusor. J Urol1998; 160: 937. Link, Google Scholar 18 : Micturition in conscious rats with and without bladder outlet obstruction: role of spinal α1-adrenoceptors. Br J Pharmacol1996; 117: 962. Google Scholar 19 : Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials1996; 17: 1. Google Scholar 20 : Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology2003; 62: 425. Google Scholar 21 : Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized placebo controlled trial. J Urol2003; 169: 592. Link, Google Scholar 22 : Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol2004; 171: 1594. Link, Google Scholar 23 : Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind trial. Ann Intern Med2004; 141: 581. Google Scholar 24 : Terazosin in patients with chronic prostatitis. BJU Int2004; 94: 5. Google Scholar 25 : A randomized-placebo controlled pilot study of tamsulosin, naproxen, and combination in category IIIA/IIIB chronic prostatitis/chronic pelvic pain syndrome. J Urol2005; 173: 30. Link, Google Scholar 26 : Terazosine and tamsulosin in nonbacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl1999; 71: 283. Google Scholar 27 : Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol2001; 32: 433. Google Scholar 28 : Lower urinary tract symptoms, pain and quality of life assessment in chronic nonbacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo. Int Urol Nephrol2002; 34: 351. Google Scholar 29 : Alpha-blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH-IIIa): a prospective, placebo-controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004; 25: 169. Google Scholar 30 : The use of alfuzosin for the treatment of chronic prostatitis/chronic pelvic pain syndrome: is there a role for α-blockers?. Eur Urol2004; 3: 204. Google Scholar 31 : Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int2004; 94: 1279. Google Scholar 32 : Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004; 64: 881. Google Scholar 33 : A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol2003; 169: 1401. Link, Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of UrologyNov 9, 2018, 3:43:00 PMIdentification of α-1L and α-1A Adrenoceptors in Human Prostate by Tissue Segment Binding Volume 177Issue 1January 2007Page: 25-30 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsadrenergic α-antagonistsprostaterandomized controlled trialsprostatitispelvic painAcknowledgmentsDr. J. Curtis Nickel assisted with the literature search.MetricsAuthor Information Vibhash C. Mishra Wexham Park Hospital, London, United Kingdom More articles by this author John Browne Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom More articles by this author Mark Emberton Institute of Urology and Nephrology, University College London, London, United Kingdom More articles by this author Expand All Advertisement PDF DownloadLoading ...
Referência(s)